The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Iza-bren met both dual primary endpoints, delivering statistically significant and clinically meaningful improvements in progression-free survival
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
Subscribe To Our Newsletter & Stay Updated
